Search Results

You are looking at 1 - 3 of 3 items for

  • Author or Editor: John M. Gliatto x
  • Refine by Access: All Content x
Clear All Modify Search
in Journal of the American Veterinary Medical Association

Summary

Questionnaires were sent to veterinarians who had submitted a fibrosarcoma from a cat to the surgical pathology services of the veterinary schools of the University of Pennsylvania and Tufts University between Jan 1, 1991 and June 30, 1992. Questionnaire items included signalment, FeLV and feline immunodeficiency virus status, site of sarcoma, vaccination site, vaccines used, treatment, biologic behavior of the tumor, and final outcome. Data were analyzed, using Student’s t-test for continuous data, χ2 test for categoric data, and log-rank test for survival estimates. Comparing results for cats with vaccination-site (vs) tumors and nonvaccination-site (nvs) tumors, we determined that vs tumors developed in younger cats and were larger than nvs tumors. Although vs sarcomas were biologically aggressive and redeveloped more often than nvs sarcomas, metastasis was not detected, and cats with vs tumors survived longer than cats with nvs tumors.

Vaccination-site sarcomas developed in cats after injection of many types of vaccines, administered singularly or in combination. Of the cats in the vs group administered a single vaccine, 37% were given rabies, 33% were given feline viral rhinotracheitis/calicivirus/panleuhopenia virus, and 30% were given FeLV vaccines. Cats with vs tumors were more likely to have received FeLV vaccine and less likely to have received rabies vaccine than those with nvs tumors. Although vaccines produced by certain manufacturers were used most often in cats with vs and nvs sarcomas, it was believed that this probably represented marketing practices and brand popularity. Many of the vaccines used had aluminum and other highly immunogenic adjuvants. We hypothesized that resident fibroblasts and myofibroblasts proliferated in the cats in response to injected adjuvants or other vaccine components, and, in some cats, these cells eventually underwent neoplastic transformation.

Free access
in Journal of the American Veterinary Medical Association

Abstract

Objective—To characterize the signalment, clinical signs, biological behavior, and response to treatment of carcinoma of the apocrine glands of the anal sac in dogs.

Design—Retrospective study.

Animals—113 dogs with histologically confirmed carcinoma of the apocrine glands of the anal sac.

Procedure—Data on signalment, clinical signs, and staging were reviewed and analyzed along with treatment modality for potential association with survival time.

Results—Sex distribution was approximately equal (54% female, 46% male). One hundred four dogs underwent treatment consisting of surgery, radiation therapy, chemotherapy, or multimodal treatment. Median survival for treated dogs was 544 days (range, 0 to 1,873 days). Dogs treated with chemotherapy alone had significantly shorter survival (median, 212 days) than those receiving other treatments (median, 584 days). Dogs not treated with surgery had significantly shorter survival (median, 402 days) than those that underwent surgery as part of their treatment (median, 548 days). Dogs with tumors ≥ 10 cm2 had significantly shorter survival (median, 292 days) than dogs with tumors ≥ 10 cm2 (median, 584 days). Hypercalcemia was identified in 27% (n = 29) of dogs, and those dogs had significantly shorter survival (median, 256 days), compared with those that were normocalcemic (median, 584 days). Dogs with pulmonary metastasis had significantly shorter survival (median, 219 days) than dogs without evidence of pulmonary metastasis (median, 548 days).

Conclusions and Clinical Relevance—Unlike most previous reports, this study revealed an approximately equal sex distribution, and results suggest a more favorable prognosis. (J Am Vet Med Assoc 2003;223: 825–831)

Full access
in Journal of the American Veterinary Medical Association